The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Ryan Zimmerman - BTIG - Analyst
: Good morning and thanks for taking the questions, guys. I guess, to start on ALLY, it sounds like you're really having good momentum here. Nick,
maybe just to start, Nick, for you on feedback on ALLY and kind of your existing user base.
I mean, I appreciate it all the time saving metric you're giving. But just maybe more qualitatively, kind of what you're hearing from the field about
their use of ALLY? How they think about it in the context of other systems? And then I have some other follow-ups.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 09, 2023 / 1:30PM, LNSR.OQ - Q3 2023 LENSAR Inc Earnings Call
Question: Ryan Zimmerman - BTIG - Analyst
: Okay. And maybe to -- yeah, no, that was great, Nick. And then I have a couple of others. I'm going to keep rolling here. But Tom, I mean, it looks
like there was limited leasing, I mean, you still grew through leasing this quarter, but limited leasing.
And if I just step back and thinking about kind of the health of your customer base, it seems like you're not seeing any impact on capital demand,
particularly in terms of the outright sale dynamics of the system relative to maybe, people. I guess I would think more people would want to lease
it, although with rates higher, maybe that's not the case.
I'm just curious if you could kind of comment on kind of how you think about the macro environment in ophthalmic practices today in terms of
capital demand and kind of what your mix of sales versus lease says about the customer base?
Question: Ryan Zimmerman - BTIG - Analyst
: Okay. Very good. And then a couple more for me. So I saw [Earthley] submitted its 510(k), I think that was public last week at AAO for the
phacoemulsification component. I'm just wondering, Nick, if you want to comment and kind of when they could potentially be on the market with
that and how it impacts maybe either the customer base or commercialization plans in the future?
Question: Ryan Zimmerman - BTIG - Analyst
: Yeah. Okay. Fair enough. And then last one for me, the additional salespeople you're planning to hire and some of these new roles, I appreciate
your color on that. Just help us understand what that cadence looks like? When those people -- you expect to potentially have those people in
place. When they could be productive? And just how to think about that impact from the additional salespeople as we move into 2024?
Question: Ryan Zimmerman - BTIG - Analyst
: Got it. All right. Thank you for taking my questions.
|
